Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Purchases C$19,500.00 in Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Bernard Lim purchased 10,000 shares of Cardiol Therapeutics stock in a transaction that occurred on Tuesday, December 17th. The stock was acquired at an average cost of C$1.95 per share, with a total value of C$19,500.00.

Cardiol Therapeutics Stock Down 2.1 %

CRDL traded down C$0.04 on Tuesday, reaching C$1.87. The company’s stock had a trading volume of 44,230 shares, compared to its average volume of 134,623. The stock has a market cap of C$130.68 million, a price-to-earnings ratio of -4.33 and a beta of 0.70. Cardiol Therapeutics Inc. has a 1 year low of C$1.07 and a 1 year high of C$4.26. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84. The business’s 50 day moving average is C$2.43 and its 200 day moving average is C$2.74.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.